| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Chief Financial Officer | Chief Financial Officer
1 company
Hohl Benjamin is a Chief Financial Officer at Enliven Therapeutics, Inc.. Recent SEC Form 4 filings include 0 buys and 9 sells.
Estimated insider holdings value: $1.6M based on current market prices.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Mar 27, 2024 | ELVN Enliven Therapeutics, Inc. | Chief Financial Officer | Sale+OE | 3,250 | $18.25 | $59,302.37 | -94.7% | +15.2% | +15.5% | |
| Feb 27, 2024 | ELVN Enliven Therapeutics, Inc. | Chief Financial Officer | Sale+OE | 3,250 | $16.97 | $55,162.90 | -100% | +31.3% | +14.7% | |
| Jan 29, 2024 | ELVN Enliven Therapeutics, Inc. | Chief Financial Officer | Sale+OE | 3,250 | $15.81 | $51,388.35 | -100% | +7.5% | +27.1% | |
| Jan 2, 2024 | ELVN Enliven Therapeutics, Inc. | Chief Financial Officer | Sale+OE | 11,870 | $15.02 | $178,326.88 | -100% | +26.8% | +60.4% | |
| Dec 26, 2023 | ELVN Enliven Therapeutics, Inc. | Chief Financial Officer | Sale+OE | 1,130 | $15.07 | $17,024.98 | -100% | +22.7% | +56.7% |